Oncos Therapeutics successfully initiates Phase I clinical study
Oncos Therapeutics initiates Phase I clinical study of CGTG-102, an oncolytic adenovirus for the treatment of solid tumor cancers May 29, 2012. Helsinki, Finland - Oncos Therapeutics today announced the successful initiation of its Phase I clinical study of CGTG-102, an oncolytic adenovirus suggested as a potential new treatment for many types of solid tumors. The first patients have already completed the safety assessment part of the study. "We are proud to be the first clinic in Northern Europe to start a clinical study with oncolytic viruses", comments the Principal Investigator of